Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination

Understanding the T-cell responses involved in inhibiting COVID-19 severity is crucial for developing new therapeutic and vaccine strategies. Here, we characterized SARS-CoV-2 spike-specific CD8(+) T cells in vaccinees longitudinally. The BNT162b2 mRNA vaccine can induce spike-specific CD8(+) T cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogimori, Takuto, Suzuki, Koichiro, Masuta, Yuji, Washizaki, Ayaka, Yagoto, Mika, Ikeda, Mami, Katayama, Yuki, Kanda, Hidenori, Takada, Minoru, Minami, Shohei, Kobayashi, Takeshi, Takahama, Shokichi, Yoshioka, Yasuo, Yamamoto, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845949/
https://www.ncbi.nlm.nih.gov/pubmed/36685601
http://dx.doi.org/10.3389/fimmu.2022.1081047
Descripción
Sumario:Understanding the T-cell responses involved in inhibiting COVID-19 severity is crucial for developing new therapeutic and vaccine strategies. Here, we characterized SARS-CoV-2 spike-specific CD8(+) T cells in vaccinees longitudinally. The BNT162b2 mRNA vaccine can induce spike-specific CD8(+) T cells cross-reacting to BA.1, whereas the T-cell receptor (TCR) repertoire usages decreased with time. Furthermore the mRNA vaccine induced spike-specific CD8(+) T cells subpopulation expressing Granzyme A (GZMA), Granzyme B (GZMB) and Perforin simultaneously in healthy donors at 4 weeks after the second vaccination. The induced subpopulation was not maintained at 12 weeks after the second vaccination. Incorporating factors that efficiently induce CD8(+) T cells with highly cytotoxic activity could improve future vaccine efficacy against such variants.

Ejemplares similares